Education
About Us
Working with TipRanks
Follow Us
Citius Oncology (CTOR)
NASDAQ:CTOR
CTOR Stock Chart & Stats
$1.07
-$0.06(-4.78%)
At close: 4:00 PM EST
$1.07
-$0.06(-4.78%)
Day’s Range― - ―
52-Week Range$0.55 - $6.19
Previous CloseN/A
Volume120.49K
Average Volume (3M)234.01K
Market Cap
$98.87M
Enterprise Value$95.37M
Total Cash (Recent Filing)$7.30M
Total Debt (Recent Filing)$3.80M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
May 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding88,275,210
10 Day Avg. Volume272,668
30 Day Avg. Volume234,012
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue24.18
Enterprise Value/Gross Profit30.23
Enterprise Value/Ebitda-4.39
Forecast
1Y Price Target
$6.00Price Target Upside460.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$38.87M
Bulls Say, Bears Say
Bulls Say
FDA-approved Product LaunchFDA approval and commercial launch of LYMPHIR is a structural milestone that moves the company from purely clinical-stage toward commercial-stage. This provides a clear path to initial revenue, supports building a commercial infrastructure, and enhances partnership or licensing prospects over the coming months.
Low LeverageRelatively low debt and a modest debt-to-equity profile give Citius financial flexibility to fund near-term commercialization and R&D without heavy interest burdens. This structural balance sheet strength reduces immediate solvency risk and supports strategic options over the medium term.
Recent Committed FinancingThe ~$18M financing materially extends runway for commercial launch activities and general corporate purposes. This capital provides time to scale sales efforts, collect early-market data, and pursue partnering discussions, making execution of commercialization plans more feasible over the next several months.
Bears Say
Pre-revenue With Widening LossesRemaining pre-revenue while losses have materially increased signals a prolonged path to profitability. Expanding operating losses erode equity and raise the likelihood the company must secure additional funding before meaningful product sales ramp, increasing structural execution and financing risk.
Negative Operating And Free Cash FlowWorsening operating cash flow and larger negative free cash flow indicate growing cash burn that must be funded externally. Structurally, persistent negative cash generation compresses strategic optionality, raises dilution risk, and can force concessions in future financings if sales do not materialize quickly.
Financing Terms And Dilution RiskWarrant repricing and amended debt terms suggest financings required investor concessions, creating potential equity overhang and dilution. Structurally, reliance on such transactions can depress shareholder value and signal tougher future financing conditions if commercialization cash flows fall short.
Citius Oncology News
CTOR FAQ
What was Citius Oncology’s price range in the past 12 months?
Citius Oncology lowest stock price was $0.55 and its highest was $6.19 in the past 12 months.
What is Citius Oncology’s market cap?
Citius Oncology’s market cap is $98.87M.
When is Citius Oncology’s upcoming earnings report date?
Citius Oncology’s upcoming earnings report date is May 20, 2026 which is in 79 days.
How were Citius Oncology’s earnings last quarter?
Citius Oncology released its earnings results on Feb 13, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.04 by -$0.02.
Is Citius Oncology overvalued?
According to Wall Street analysts Citius Oncology’s price is currently Undervalued.
Does Citius Oncology pay dividends?
Citius Oncology does not currently pay dividends.
What is Citius Oncology’s EPS estimate?
Citius Oncology’s EPS estimate is -0.01.
How many shares outstanding does Citius Oncology have?
Citius Oncology has 88,275,210 shares outstanding.
What happened to Citius Oncology’s price movement after its last earnings report?
Citius Oncology reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.04. Following the earnings report the stock price went up 3.39%.
Which hedge fund is a major shareholder of Citius Oncology?
Currently, no hedge funds are holding shares in CTOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Citius Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (460.75% Upside)
$6.00 (460.75% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
85.87%
Trailing 12-Months
Company Description
Citius Oncology
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
CTOR Stock 12 Month Forecast
Average Price Target
$6.00
▲(460.75% Upside)
Technical Analysis
Ownership Overview
6.93% Insiders
0.29% Mutual Funds
6.46% Other Institutional Investors
85.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---